Newsroom

LATEST PUBLICATIONS

Leveraging Standardized MRD Assays to Guide CLL Treatment

wmm2024-01-25T10:44:11-08:00January 25th, 2024|

Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

wmm2023-04-10T20:22:16-07:00March 23rd, 2023|

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant

Invivoscribe Marketing2024-08-02T14:22:45-07:00March 7th, 2023|

Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

wmm2023-04-10T20:24:04-07:00March 2nd, 2023|

Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples

wmm2022-12-29T21:22:21-08:00November 15th, 2022|

Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay

Invivoscribe Marketing2023-05-11T03:12:47-07:00May 11th, 2023|

Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in China

Invivoscribe Marketing2023-02-23T06:28:40-08:00February 23rd, 2023|

Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan)

Invivoscribe Marketing2023-02-01T21:02:16-08:00February 1st, 2023|

Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AML

wmm2022-10-24T14:57:12-07:00October 24th, 2022|

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML

Invivoscribe Marketing2022-08-16T20:08:13-07:00August 16th, 2022|

EA4HP-SH 2024

September 21 – 26, 2024
Dubrovnik, Croatia
On-site Booth & Live Presentation in Exhibition
https://www.ea4hp-sh2024.com/

CMACSH Chinese Society of Hematology Conference 2024

September 20-22, 2024
Wuhan, China
On-site Booth
https://cmacsh2024.sciconf.cn/cn/web/index/

JCA Annual Meeting 2024

September 19-21, 2024
Fukuoka, Japan
On-site Booth
https://site.convention.co.jp/jca2024/en/

CGC Annual Meeting 2024

August 4-7, 2024
St. Louis, MO, US
On-site Booth
https://cancergenomics.org/meetings/cgc_annual_meeting_2024.php

JSLH 2024

July 20-21, 2024
Hiroshima, Japan
On-site Booth
https://med-gakkai.jp/jslh25/

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

CE-IVD

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

CE-IVD

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Myeloma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

Newsroom

Newsroom

LATEST PUBLICATIONS

LATEST PRESS

CONFERENCES

EA4HP-SH 2024

CMACSH Chinese Society of Hematology Conference 2024

JCA Annual Meeting 2024

CGC Annual Meeting 2024

JSLH 2024

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.